CG MedTech H1 Consolidated Profit Drops 77% Despite Sales Growth
South Korean orthopedic and dental implant maker CG MedTech reported a significant decline in first-half consolidated operating profit. This occurred despite an increase in consolidated sales, as the company absorbed costs from new subsidiaries and business expansion investments.
First-Half Financial Performance Shows Profit Decline
CG MedTech's consolidated operating profit for the first half fell 77.2 percent, reaching 570 million won. This reduction happened even as consolidated sales rose 16.3 percent, totaling 28.35 billion won. The company stated that costs for stabilizing newly consolidated subsidiaries and upfront investments for business expansion affected this profitability.
In contrast, standalone sales increased 35.1 percent year-on-year to 17.72 billion won. Standalone operating profit also rose 3.8 percent to 1.4 billion won, with gross profit up 17.7 percent to 7.77 billion won.
Core Medical Device Business Drives Standalone Growth
The company's core medical device business showed growth across both domestic and overseas markets. Standalone domestic sales increased 38.3 percent year-over-year, driven by a sales structure reorganization and higher sales of spinal implants. Overseas sales for standalone operations rose 31.8 percent.
Specific product lines, including SPINE, bone graft gel products, and Novosis Trauma (an rhBMP-2-based bone graft substitute), contributed to this domestic growth. To support demand, CG MedTech completed a new plant in Uijeongbu, Gyeonggi Province, this year.
This 12.3 billion won investment expands automated metal-processing capacity for orthopedic and spinal implants, alongside production infrastructure for 3D-printed products. Commercial production has commenced, with plans to stabilize processes in the second half.
Diversification into Digital Dentistry and Regenerative Medicine
CG MedTech is expanding its capabilities in digital dentistry and human tissue-based regenerative medicine. The company integrated digital design and development through a merger with GDS. Acquisitions of All About Abutment and Dental Ocean further expanded its capacity in custom abutment manufacturing and implant fixture development.
In regenerative medicine, CG MedTech secured a human tissue processing facility in Seongnam, Gyeonggi Province, in April, and obtained a tissue bank license change for REGEN Hub in July. It has established a platform for human extracellular matrix (hECM) tissue products and bone regeneration products.
The company plans to produce its own products and offer contract development and manufacturing organization (CDMO) services for hECM. CG MedTech targets 100 billion won in annual sales by 2028, driven by these strategic expansions.
What This Means for Asia's Beauty Economy
CG MedTech's strategic investments into human tissue-based regenerative medicine and CDMO services could open new avenues for Asia's medical aesthetics and advanced ingredient sectors.
As the company stabilizes its production of hECM tissue products and offers CDMO capabilities, beauty brands and professional clinics seeking innovative, science-backed components for high-performance formulations or aesthetic treatments may find new sourcing and partnership opportunities.
This expansion demonstrates a move towards specialized, high-value ingredients and manufacturing, which could influence supplier choices for premium beauty and medical aesthetic product development across Asia.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
